A 26-year-old woman presents with the sudden onset of left chest pain and dyspnea while at rest. She has never smoked. Two months ago, she developed a right-sided pneumothorax, which was treated with a tube thoracostomy. At that time, she received a diagnosis of tuberous sclerosis complex.

She has no other medical problems, has no history of trauma, and has tested negative for human immunodeficiency virus (HIV).

On physical examination, her breath sounds in the left hemithorax are decreased. She also has many nodular lesions on her face (Figure 1), a hypopigmented lesion on her right thigh (Figure 2), and a fleshy plaque on her lower back (Figure 3).

Radiography (Figure 4) and computed tomography (CT) of the chest (Figure 5) reveal a left-sided pneumothorax, a small right-sided pneumothorax, and diffuse, bilateral, thin-walled cysts in the lung.

Q: Which is the most likely diagnosis?

- Pulmonary Langerhans cell histiocytosis
- Cystic fibrosis
- Pneumocystis jirovecii pneumonia
- Alpha-1 antitrypsin deficiency
- Tuberous sclerosis complex with lymphangioleiomyomatosis
A: The correct diagnosis is tuberous sclerosis complex with lymphangioleiomyomatosis. The lymphangioleiomyomatosis was suggested by the CT findings, by the recurrence of pneumothorax, and, later, by biopsy results. Lymphangioleiomyomatosis occurs in about 30% of women with the tuberous sclerosis complex. However, 10% to 15% of women with lymphangioleiomyomatosis do not have tuberous sclerosis complex, in which case the condition is called sporadic lymphangioleiomyomatosis.

Tuberous sclerosis complex can involve the nerves (seizures, brain tumors), the lungs (lymphangioleiomyomatosis, causing pneumothorax or chylothorax), and the skin; skin lesions include facial angiofibromas, ash-leaf spot, and shagreen patch. It is also associated with abdominal involvement (lymphangiomomas, renal angiomyolipomas). Lymphangioleiomyomatosis usually presents as spontaneous pneumothorax in women of childbearing age. After initial stabilization of pneumothorax with simple aspiration or thoracostomy, the patient should undergo ipsilateral chemical or surgical pleurodesis, as the risk of recurrent pneumothorax is greater than 70%. Single or bilateral lung transplantation has been accepted as therapy for end-stage pulmonary lymphangioleiomyomatosis, characterized by recurrent pneumothoraces and chylopleural fluid collections causing respiratory failure (marked dyspnea, hypoxemia, and reductions in forced expiratory volume in the first second of expiration and in diffusing capacity for carbon monoxide. Recurrence of lymphangioleiomyomatosis in the allograft lung is rare. Hormone therapies such as intramuscular progesterone, oral progestins, or gonadotropin-releasing hormone agonists have been used for lymphangioleiomyomatosis (not pneumothorax), but they are no longer recommended.

Pulmonary Langerhans cell histiocytosis, cystic fibrosis, Pneumocystis jirovecii pneumonia, and alpha-1 antitrypsin deficiency have all been associated with spontaneous pneumothorax.

Cystic fibrosis can affect multiple systems, including lung, skin, bone, and the pituitary gland. More than 90% of patients have a history of smoking. Chest radiography reveals a reticulonodular pattern with involvement of the middle and upper lobes. Later, the nodules tend to cavitate and form contiguous cysts that may mimic lymphangioleiomyomatosis on a high-resolution chest CT.

Cystic fibrosis is most often diagnosed before the age of 3. In adults, it can present as sinus and pulmonary disease (chronic cough with sputum production, chronic sinusitis with nasal polyposis, radiographic evidence of bronchiectasis and, less commonly, pneumothorax); as a gastrointestinal tract and nutritional abnormality (pancreatic insufficiency, distal intestinal obstruction, focal biliary cirrhosis); and as male infertility.

Pneumocystis jirovecii pneumonia occurs mainly in patients on chronic immunosuppressive drugs or with immune deficiency due to HIV infection. Typical radio-
graphic features are bilateral perihilar interstitial infiltrates that become increasingly homogeneous and diffuse as the disease progresses. Less common findings include solitary or multiple nodules, upper-lobe infiltrates in patients receiving aerosolized pentamidine (NebuPent), pneumatoceles, and pneumothorax.8

**Alpha-1 antitrypsin** is an inhibitor of neutrophil elastase. Deficiency is associated with severe, early-onset panacinar emphysema with a basilar predominance, with chronic liver disease including cirrhosis, and less commonly with panniculitis and vasculitis associated with antineutrophil cytoplasmic antibody.9 Coalescence of panacinar emphysema leads to the formation of bullae and is important in the development of spontaneous pneumothorax.10

The patient underwent bilateral talc pleurodesis. Lung biopsy at the same time confirmed lymphangioleiomyomatosis. One month later, the right pneumothorax recurred, and she underwent pleurodesis in the right hemithorax with tetracycline. Six months after the second pleurodesis, she was asymptomatic.

## REFERENCES


**ADDRESS:** Aditya Gupta, MD, Pulmonary, Critical Care, and Sleep Medicine, University of Texas Health Science Center, 6431 Fannin, MSB 1.266, Houston, TX 77030; e-mail Aditya.Gupta@uth.tmc.edu.

**Financial disclosure for associate editors of the Cleveland Clinic Journal of Medicine**

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), the Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following associate editors of the Cleveland Clinic Journal of Medicine have indicated that they may have a relationship which, in the context of their contributions, could be perceived as a conflict of interest:

**DANIEL J. BROTMAN, MD**
Advisory board: Canyon Pharmaceuticals, Cubist Pharmaceuticals, Sanofi-Aventis, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, EMCREG International, Otsuka America Pharmaceutical, Ortho-McNeil Pharmaceuticals, Johnson & Johnson Hospitalist leadership panel: Quantia Communications Research support: Siemens Healthcare Diagnostics

**GARY FRANCIS, MD**
Data and safety monitoring board: Novartis

**AMIR K. JAFFER, MD**
Consulting: Canyon Pharmaceuticals
Consulting; teaching and speaking: Sanofi-Aventis Pharmaceuticals

**MISTRY C. LEONARD, PharmD**
Consulting; teaching and speaking; advisory committee, or review panel: Amgen

**ANGELA A. LICATA, MD, PhD**
Consulting: teaching and speaking; independent contractor: Novartis, Eli Lilly, Amgen

**ATUL C. MEHTA, MD**
Consulting: teaching and speaking: Sanofi-Aventis Pharmaceuticals, Merck & Co

**BERNARD J. SILVER, MD**
Teaching and speaking: Talecris Biotherapeutics

**TYLER STEVENS, MD**
Consulting: Boston Scientific
Research funding: Abbott Pharmaceuticals

**THEODORE SUH, MD, PhD, MHS**
Teaching and speaking: Novartis
Ownership interest: GlaxoSmithKline

**DONALD G. VIDT, MD**
Independent contractor (research), trial design: AstraZeneca

**WILLIAM S. WILKE, MD**
Consulting: UCB, Pfizer

All other associate editors have indicated they have no relationship that in the context of their contributions could be perceived as a conflict of interest. Disclosures for editors and editorial staff can be found on page 340.

---

**CME ANSWERS** Answers to the credit tests on page 399 of this issue

Inhaled steroids for mild asthma 1E 2B
Bleeding after acute coronary syndromes 1A 2D
Left ventricular hypertrophy 1B 2A
Hirsutism 1A 2B